Quick Answer
LENZ Therapeutics, Inc. reported Total Revenue of $19.09 million for fiscal year 2025.
LENZ Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $19.09M | $0.00 | — | — | — | — |
| Revenue (ASC 606) | $19.09M | $0.00 | — | — | — | — |
| Net Income | -$82.13M -65.0% |
-$49.77M +28.9% |
-$69.97M +30.8% |
-$101.05M -42.8% |
-$70.76M | — |
| Diluted EPS | -$2.85 -21.8% |
-$2.34 +93.4% |
-$35.71 -1840.8% |
-$1.84 +24.9% |
-$2.45 | — |
| Total Assets | $305.88M +42.1% |
$215.30M +205.9% |
$70.38M -78.1% |
$321.90M -19.9% |
$401.99M +1681.5% |
$22.56M |
| Cash and Equivalents | $25.18M +24.9% |
$20.16M -42.6% |
$35.14M -26.4% |
$47.73M -87.3% |
$376.98M +1805.7% |
$19.78M |
| Stockholders Equity | $284.34M +39.3% |
$204.08M +320.1% |
-$92.71M -283.6% |
-$24.17M -106.3% |
$384.05M +687.2% |
-$65.41M -2849.0% |
| R&D Expense | $18.67M -37.4% |
$29.80M -49.9% |
$59.50M -18.2% |
$72.79M +91.9% |
$37.93M +315.8% |
$9.12M |
| Operating Income | -$91.14M -55.5% |
-$58.61M +19.1% |
-$72.43M +31.4% |
-$105.64M -74.8% |
-$60.44M -347.7% |
-$13.50M |
| Shares Outstanding | 31.34M +13.9% |
27.52M +1297.3% |
1.97M -96.6% |
58.22M +0.4% |
58.01M +464.4% |
10.28M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$16.70M | -63.5% | -12.0% |
| Diluted EPS | September 30, 2025 | -$0.59 | -55.3% | -11.3% |
| Total Assets | September 30, 2025 | $210.70M | -5.9% | -3.0% |
| Cash and Equivalents | September 30, 2025 | $25.40M | -38.1% | -32.5% |
| Stockholders Equity | September 30, 2025 | $193.93M | -9.9% | -6.0% |
| R&D Expense | September 30, 2025 | $3.79M | -41.2% | -58.2% |
| Operating Income | September 30, 2025 | -$18.89M | -45.9% | -12.0% |
| Shares Outstanding | September 30, 2025 | 28.59M | +4.0% | +0.3% |
- LENZ Therapeutics, Inc. reported Total Revenue of $19.09 million for fiscal year 2025.
- LENZ Therapeutics, Inc. reported Revenue (ASC 606) of $19.09 million for fiscal year 2025.
- LENZ Therapeutics, Inc. reported Net Income of -$82.13 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed a decrease of -65.0% in Net Income compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Diluted EPS of $2.85 per share (loss) for fiscal year 2025.
- LENZ Therapeutics, Inc. showed a decrease of -21.8% in Diluted EPS compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Total Assets of $305.88 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed an increase of +42.1% in Total Assets compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Cash and Equivalents of $25.18 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed an increase of +24.9% in Cash and Equivalents compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Stockholders Equity of $284.34 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed an increase of +39.3% in Stockholders Equity compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported R&D Expense of $18.67 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed a decrease of -37.4% in R&D Expense compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Operating Income of -$91.14 million for fiscal year 2025.
- LENZ Therapeutics, Inc. showed a decrease of -55.5% in Operating Income compared to the prior fiscal year.
- LENZ Therapeutics, Inc. reported Shares Outstanding of 31.34 million shares for fiscal year 2025.
- LENZ Therapeutics, Inc. showed an increase of +13.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: